Ready Aim Omicron!
Bloomberg Businessweek|December 06, 2021
Drugmakers always knew variants would arise. The latest will test their preparedness
Cynthia Koons, with Robert Langreth and Emma Court

Big Pharma’s traditional playbook for developing medicines required years of data collection and trials before a treatment began its life saving tenure. But drugmakers last year pulled off the onceunthinkable feat of developing a vaccine against Covid-19 in less than a year. Now they’re racing even faster to adapt those shots to protect against the new omicron variant in as little as six weeks. While it may take almost that long to determine if new vaccines are truly needed to deal with the coronavirus’s latest iteration, waiting simply isn’t an option.

This is the scramble that Covid has created. The virus is so destructive that drugmakers have started scientific work to adapt vaccines before it’s even clear the changes will be necessary. The pandemic has allowed pharma giants to leverage mRNA and other new technologies to dramatically speed up research and development. They’re now faced with having to speed things up yet again to contend with the onslaught of variants.

“We have been preparing for a moment like that for months,” Albert Bourla, chief executive officer of Pfizer Inc., said of the emergence of omicron in an interview with Bloomberg Television. “I feel comfortable that the playbook will work.”

Pfizer started working on a vaccine tailored to stop omicron on Nov. 26, immediately after it was identified. Rival Moderna Inc. mobilized its employees a day earlier—on Thanksgiving Day—to do the same. One reason the two companies can move so quickly is that their mRNA vaccines don’t require growing viruses or proteins in live cells as do traditional vaccine technologies. All that scientists actually need to build an mRNA vaccine is the sequence of a given virus.

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM BLOOMBERG BUSINESSWEEKView All

The Fed's Mind Control

The idea that monetary policy shapes inflation expectations is about to get road-tested

5 mins read
Bloomberg Businessweek
January 24, 2022

Sheltered Paradise

With spectacular beaches, top-tier resorts, and a stellar Covid record, Anguilla is growing even more irresistible.

6 mins read
Bloomberg Businessweek
January 24, 2022

Same City - Different Games

What’s changed since Beijing last held the Olympics? Almost everything

4 mins read
Bloomberg Businessweek
January 24, 2022

Keeping Covid Out of The Cabin

As the pandemic enters Year 3, airlines are stepping up their hygiene routines

4 mins read
Bloomberg Businessweek
January 24, 2022

Boxed In on China

Biden’s inability to extract concessions from Beijing is a liability going into November’s midterms

5 mins read
Bloomberg Businessweek
January 24, 2022

Revisit Your Retirement Strategy

High valuations, rising interest rates, and spiking inflation make it time for a checkup

6 mins read
Bloomberg Businessweek
January 24, 2022

Ponzi schemer On the Pacific

Gina Champion-Cain was a beloved friend, mentor, and pillar of the San Diego business community. But her successful image and lavish lifestyle were fueled by a $400 million fraud

10+ mins read
Bloomberg Businessweek
January 24, 2022

How Did Blake Hall Get Between You And Your Identity?

During the pandemic his online-authentication company, ID.me, became the government’s digital gatekeeper. And its grip is only getting tighter

10+ mins read
Bloomberg Businessweek
January 24, 2022

Biden's Year 2 Test

As the pandemic wears on and prices rise, many Americans are disillusioned with the president. Can he win them back?

10+ mins read
Bloomberg Businessweek
January 24, 2022

A FIGHT OVER DISCRIMINATION IN THE AGE OF ALGORITHMS

Redfin has staked its reputation on making a racist industry more equitable. Critics say it’s been denying services to Black homebuyers and sellers

10+ mins read
Bloomberg Businessweek
January 24, 2022
RELATED STORIES

The World's 50 Most Innovative Companies – Biotech

Mariana Matus Cofounder and CEO of Biobot Analytics

3 mins read
Fast Company
March - April 2021

The Last Pandemic

Technological breakthroughs and policy progress mean humanity may never again have to endure a disaster like Covid-19.

10+ mins read
Reason magazine
May 2021

Facebook Steps Up Vaccine Misinfo Efforts. Will It Work?

As inoculation efforts for the coronavirus ramp up around the world, Facebook says it’s going all in to block the spread of bogus vaccine claims.

1 min read
AppleMagazine
Feburary 12, 2021

BRITAIN TO TEST MIXING AND MATCHING OF COVID-19 VACCINES

British scientists are starting a study Thursday to find out if it’s OK to mix and match COVID-19 vaccines.

2 mins read
Techlife News
Techlife News #484

COVID VIRUS MUTATING OUT OF CONTROL

New strains may prove DEADLIER!

3 mins read
National Enquirer
February 08, 2021

Can Covid-19 Vaccines Be Mixed And Matched?

Can COVID-19 vaccines be mixed and matched?

1 min read
AppleMagazine
AppleMagazine #483

WILL YOU GET THE COVID-19 VACCINE?

With several promising COVID-19 vaccines on the horizon including Moderna and Pfizer, many Americans will soon be faced with the decision of whether or not get vaccinated.

1 min read
Natural Solutions
December 2020

HOW THE RICH & FAMOUS GET COVID VACCINE FIRST!

Money talks on thriving black market for life-saving shots

3 mins read
National Enquirer
January 04, 2021

In Defense of Covid Billionaires

People love to hate billionaires. And they really love to hate large pharmaceutical companies.

7 mins read
Reason magazine
February 2021

True Stories

To beat anti-science trolls, sometimes you have to think like one.

4 mins read
Mother Jones
January/February 2021